Biogen (BIIB) said Monday that it has signed a deal with Dublin-based Alkermes (ALKS) to develop and market a drug in late-stage clinical trials to treat relapsing forms of multiple sclerosis.

Under the agreement, Biogen will receive an exclusive, worldwide license to market the experimental oral medicine, called ALKS 8700, and will pay Alkermes a royalty on worldwide scales in the mid-teens.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy